Physician profile
Frederick Peter Jaecklein
NPI 1306828009
$1,049.24
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $96.84 · 2021: $303 · 2022: $182 · 2023: $34.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $160.03 | 2019-2021 | |
| Boston Scientific Corporation | $125.19 | 2022-2023 | Eluvia |
| W. L. Gore & Associates, INC. | $116.19 | 2019 | |
| Merck Sharp & Dohme LLC | $83.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $82.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $65.59 | 2019-2022 | |
| Novo Nordisk INC | $42.71 | 2019-2020 | |
| Abbott Laboratories | $39.05 | 2021 | |
| Opko Pharmaceuticals, LLC | $33.06 | 2020-2022 | |
| Ucb, INC. | $29.40 | 2021-2022 | |
| Horizon Therapeutics Plc | $29.08 | 2021 | |
| Alexion Pharmaceuticals, INC. | $28.91 | 2021-2022 | |
| Amgen INC. | $27.10 | 2020-2021 | |
| Glaxosmithkline, LLC. | $22.11 | 2021 | |
| Pfizer INC. | $20.86 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.06 | 2021 | |
| Abbvie INC. | $18.73 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.97 | 2019 | |
| Insmed, INC. | $17.88 | 2021 | |
| Celgene Corporation | $14.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.55 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.25 | 2019 | |
| Dexcom, INC. | $10.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Jaecklein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.